艾伯维2024年Q3财报显示，净收入达144.6亿美元，同比增长3.8%。尽管“药王”Humira因仿制药冲击收入暴跌37.2%，但免疫学双药Skyrizi和Rinvoq合计创收48.19亿美元，增速超45%，填补了Humira的缺口。Skyrizi单季销售32.05亿美元，同比激增50.8%；Rinvoq收入16.14亿美元，同比增长45.3%。这两款药物的实际收入比预期高出1.85亿美元，推动...
Source Link艾伯维2024年Q3财报显示，净收入达144.6亿美元，同比增长3.8%。尽管“药王”Humira因仿制药冲击收入暴跌37.2%，但免疫学双药Skyrizi和Rinvoq合计创收48.19亿美元，增速超45%，填补了Humira的缺口。Skyrizi单季销售32.05亿美元，同比激增50.8%；Rinvoq收入16.14亿美元，同比增长45.3%。这两款药物的实际收入比预期高出1.85亿美元，推动...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.